Woolley AE, et al. - Researchers assessed if the use of direct-acting antiviral agents has substantially increased the donor organ pool by allowing transplantation of hearts and lungs from hepatitis C virus (HCV)-infected donors into recipients without HCV infection. They assessed transplantation of hearts and lungs from donors who had hepatitis C viremia to adults without HCV infection, regardless of HCV genotype. In total, 44 patients (36 received lung transplants and 8 received heart transplants) were recruited. A 4-week course of antiviral therapy, started within hours of transplantation, in patients with no HCV infection who got a heart or lung transplant from donors with hepatitis C viremia prevented HCV infection in these patients. No serious adverse events related to treatment have been identified.